Síndrome antifosfolípido catastrófico
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
Paciente de sexo femenino, 26 años de edad, con historia de Lupus eritematoso sistémico, Paniculitis lúpica y Síndrome antifosfolípido. Ingresa a urgencias por dos días de evolución, consistente en astenia, fiebre y sangrado profuso de úlceras en miembros inferiores. En el examen físico se encuentra edema generalizado y taquicardia, las pruebas solicitadas demuestran anormalidades en la coagulación, alteraciones en el complemento y en las enzimas hepáticas, se documenta la presencia de bacteriemia por Estreptococo spp, se hospitaliza y se inicia manejo antibiótico. Durante su estadía en el hospital presenta deterioro rápido y severo de su estado de salud y, a pesar del tratamiento, desarrolla una insuficiencia multiorgánica que la conduce a la muerte en tan solo siete días de iniciado el cuadro clínico.
Citas
Piette J-C, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y. The catastrophic antiphospholipid syndrome—Asherson’s syndrome. Ann Med Internet. 2003;154:195-6.
Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530-4.
Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508–12.
Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid Syndrome Clinical and Immunologic manifestations and Patterns of Disease Expression in a Cohort of 1,000 Patients. Arthritis Rheum. 2002 Apr;46(4):1019-27.
Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G,Petri MA, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001;80:355–77.
Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum. 2003 Dec;48(12):3320-7.
Asherson RA, Espinosa G, Menahem S, Yinh J, Bucciarelli S, Bosch X, et al. Relapsing catastrophic Antiphospholipid Syndrome: report of three cases. Semin Arthritis Rheum. 2008 Jun;37(6):366- 72.
Asherson R. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson’s) syndrome. Immunobiology. 2005;210(10):727-33.
Ortega-Hernandez OD, Agmon-Levin N, Blank M, Asherson R, Shoenfeld Y. The physiopathology of the catastrophic antiphospholipid (Asherson’s) syndrome: compelling evidence. J Autoimmun. 2009;32:1–6.
Asherson R. The catastrophic antiphospholipid (Asherson’s) syndrome. Autoimmun Rev. 2006 Dec;6(2):64-7.
Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of the catastrophic antiphospholipid syndrome-molecular mimicry? J Rheumatol. 2000;27:12–5.
Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med.1998;104:381–5.
Raschi E, Testoni C, Borghi MO, Fineschi S, Meroni PL. Endothelium activation in the antiphospholipid syndrome. Biomed Pharmacother. 2003;7:282–6.
Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG,Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody mediated thrombosis. Arthritis Rheum. 2005;52:2120–4.
Hart ML, Ceonzo KA, Shaffer LA, Takahashi K, Rother RP, Reenstra WR, et al. Gastrointestinal ischemia–reperfusion is lectin complement pathway dependent without involving C1q. J Immunol. 2004 Dec 1;173(11):7055-61.
Fleming SD, Egan RE, Chai C, Girardi G, Holers VM, Salmon J, et al. Anti-phospholipid antibodies restore mesenteric ischemia reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol. 2005;173:7055–61.
Asherson RA. Acute respiratory distress syndrome and other unusual manifestations of the catastrophic antiphospholipid (Asherson’s) syndrome. Isr Med Assoc J. 2004 Jun;6(6):360-3.
Espinosa G, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome and sepsis. A common link? J Rheumatol. 2007 May;34(5):923-6.
Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson’s) syndrome. Immunobiology.2005;210(10):727-33.
Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006 Aug;54(8):2568-76.
Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, De la Red G, et al. Thrombotic microangiopathic hemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730– 6
Asherson RA, Espinosa G, Cervera R, Gómez-Puerta JA, Musuruana J, Bucciarelli S, et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis. 2005 Jun;64(6):943-6.
Cervera R, Gómez-Puerta JA, Cucho M, Espinosa G, Font J, De la Red G, et al. Catastrophic antiphospholipid syndrome (CAPS): analysis of the international consensus statement on preliminary classification criteria for CAPS using the ‘‘CAPS Registry’’. Ann Rheum Dis. 2003;62(Suppl 1):88
Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Ann Rheum Dis.1998 May;77(3):195- 207.
Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Ann Rheum Dis.2001 Nov;80(6):355-77.
Amital H, Levy Y, Davidson C, Lundberg I, Harju A, Kosach Y, et al. Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases. Semin Arthritis Rheum. 2001 Oct;31(2):127-32.
Spinnato JA, Clark AL, Pierangeli SS, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol. 1995;172:690–4.
Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003 Jun;62(6):530-3.